User:Lan.wang17/Enter your new article name here

Matthew Chervenak is the founder, President and CEO of General Biologic (GBI), a China-focused healthcare consulting and data intelligence company. He also serves as the Chairman of the Shanghai American Chamber of Commerce- Healthcare Committee. Prior to establishing General Biologic, Chervenak was a strategist at Sapient Corporation in New York City and researcher at New York University Medical Center and the National Institutes of Health. Chervenak graduated with a B.S. in Biology from Pennsylvania State University.

Chervenak regularly contributes to international publications and speaks at industry conferences about China's pharmaceutical and biotechnology sectors. Chervenak believes that China is an ideal base for global biogenerics. In his China Business Review editorial, Chervenak said that China's low-cost, highly skilled technologists and scientists, a strong track record in life-science research, a high-quality returnee pool, advantageous policies and tax treatment, and China's entrepreneurial culture makes it a bright future for China's life sciences industry. Even in the controversial topic of IP in the life sciences field in China, according to Chervenak, as long as a foreign biotech firm protects its IP for the most lucrative markets, it is usually not worth being overly concerned about a Chinese company violating IP use in China, where the market is still small.